BetterLife Pharma Inc (CSE:BETR, OTCQB:BETRF) announced that it has launched its newly-designed website, which can be accessed at abetterlifepharma.com.
The company said its new corporate website better presents BetterLife’s mission to develop new and innovative medicines to treat mental health disorders, such as depression and anxiety.
“We have obtained solid pre-clinical data to position BETR-001 as a leading candidate for potential treatment of certain mental health disorders affecting millions around the world. The non-hallucinogenic properties of BETR-001, combined with our proprietary non-controlled (scheduled) manufacturing process, allows for faster development and treatment of millions of additional patients,” BetterLife Pharma CEO Dr Ahmad Doroudian said in a statement.
READ: BetterLife receives positive FDA response to its pre-IND application for major depressive disorder treatment with BETR-001
“With recent guidance from the FDA (US Food and Drug Administration), we continue to generate additional data to complete our Investigational New Drug (IND) Application to be submitted second half of this year,” Doroudian added.
BetterLife Pharma is an emerging biotechnology company primarily focused on developing and commercializing two compounds, BETR-001 and BETR-002, to treat neuropsychiatric and neurological disorders.
Contact Sean at sean@proactiveinvestors.com